Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is more or less 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the first quarter of 2021.

The current consensus among 11 TipRanks analysts is actually for a modest Buy rating of shares in CVS Health, with an average price aim of $84.

The analysts priced targets range from a high of $101 to a low of $61.

From its newest earnings report, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management strategies. The retail or Long Term Care segment includes selling of prescribed drugs and assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products and related services, including medical, pharmacy, dental, behavioural health, medical relief abilities. The Corporate segment involves in offering administrative services as well as management. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.